BLUEMATRIX
24.7.2024 10:01:29 CEST | Business Wire | Press release
BlueMatrix, the world’s largest publisher of investment research, has announced that, since the start of 2024 and a strategic growth investment by leading software investment firm’s Thoma Bravo, new revenue has grown an impressive 74% on the same period last year. BlueMatrix is doubling down on its investment in its clients through a growth strategy that includes strengthening its leadership team with two major C-suite appointments. Its new Chief Financial Officer and Chief Revenue Officer have over 40 years of combined experience in scaling software companies within the financial services landscape.
Joining BlueMatrix’s leadership team, overseen by Chief Executive Officer and President Patricia Horotan and alongside Chief Operating Officer Mirko Consolascio, is Ben McFadden, appointed as Chief Financial Officer. He brings more than 15 years of enterprise software strategic finance expertise. He was previously Head of Finance at Nintex, a leader in global automation software, and Revalize, a quote-to-cash provider for manufacturing. His prior experience includes five years as a sell-side equity research analyst at Keybanc Capital Markets focused on infrastructure software.
Ben McFadden commented: “I witnessed BlueMatrix’s trajectory firsthand seven years ago as a sell-side equity analyst and now I get to be a part of this exceptional team. My focus is on maintaining our impressive 97% customer retention, enabled by our international expertise, industry-leading products, and outstanding service. With Thoma Bravo's strategic investment too, I believe the future for BlueMatrix is very bright indeed.”
Also joining BlueMatrix’s leadership team is Bryan North-Clauss, appointed as its Chief Revenue Officer. Most recently, he held the position of Chief Revenue Officer at Truv, after leading AlphaSense's financial services sales division, where he contributed to growing its annual recurring revenue by 350% and productivity per salesperson by 400%. Earlier in his career, Bryan held senior roles in fixed income sales at Deutsche Bank, Morgan Stanley, Citi, and Lehman Brothers. His career began as a founding member of software firm JobDirect.com, acquired by Korn/Ferry.
Bryan North-Clauss stated: “This is a pivotal moment for me to join BlueMatrix and contribute to its ambitious expansion plans following January’s strategic investment by Thoma Bravo. Six months in, my focus remains on reinforcing our market dominance and share in our core verticals. For instance, 75% of all sell-side research is published using the BlueMatrix platform, highlighting our strong product-market fit and commitment to delivering world-class service. Moving forward, we aim to invest further in our clients' success to drive future growth.”
BlueMatrix’s continued growth strategy will focus on moving to new markets, including Europe, APAC region, and South America, to deliver technical expertise and client experience to a new audience of global clients. There will also be increased focus on enhancing the innovation that optimises workflows, scalability, and deep integration across its entire product suite to meet the evolving needs of its worldwide client base.
Patricia Horotan, Chief Executive Officer and President of BlueMatrix, said: “Our plans to expand our platform and portfolio of products for existing and new clients alike will not only reinforce our world-leading status, but bring the most advanced investment solutions to new generations of investors. Working with my leadership team, and in partnership with Thoma Bravo, we are excited to take BlueMatrix to new markets and new audiences.”
Founded in 1999, BlueMatrix employs 147 people, with 42% in the US and 39% in Romania. Expansion into new markets, including Europe, APAC region, and South America, is planned for the second half of this year, highlighting the company's international growth.
BlueMatrix offers fully integrated, cloud-based solutions for the entire investment research production workflow, including content creation, compliance approval, distribution, hosting, and analytics. This comprehensive suite positions BlueMatrix as the only global platform covering the complete investment research lifecycle.
About BlueMatrix
BlueMatrix, the world’s largest publisher of investment research, is a pioneering SaaS provider connecting content publishers and readers. Since 1999, BlueMatrix has developed advanced research-creation and distribution software for the financial services sell side, serving over 800 banks and institutions worldwide and supporting the production and publishing of 1.4 million items annually.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724453243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom